Lexeo Therapeutics

Edit info

Founded: 2018

Location: New York, NY

Employee range: 11 - 50

Clinical stage: Clin1/Clin2

Therapy area: Batten disease (ODD)

Drug types: GEN, NEU, CVV, RAR

Lead product: LX1004

Funding: $100M Sep 2021; $85M A Jan 2021

lexeotx.com

linkedin.com

job board

Drug notes:

LX2006 Clin1/Clin2 cardiac Friedreich's ataxia; LX1001 Clin1/Clin2 Alzheimer's; LX2020 Clin0 arrhythmogenic cardiomyopathy; LX1021 RD Alzheimer's; LX2021 RD arrhythmogenic cardiomyopathy; LX2022 RD hypertrophic cardiomyopathy; LX1020 Clin0 Alzheimer's

About:

Lexeo Therapeutics is creating high-impact genetic medicines for cardiovascular diseases and APOE4-associated Alzheimer’s disease. Cardiovascular disease remains the most significant cause of morbidity and mortality in the western world and rapidly becoming a primary cause worldwide. Lexeo is developing a number of disease-modifying gene therapy candidates to treat larger-rare cardiovascular diseases. In addition, Lexeo is using their same gene therapy technology to build a pipeline of central-nervous system (CNS) focused therapies. In both the cardiac and CNS programs Lexeo is advancing their pipeline into clinical trials.